What is William Blair’s Estimate for SLDB FY2025 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at William Blair increased their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a research report issued to clients and investors on Tuesday, November 4th. William Blair analyst S. Corwin now anticipates that the company will earn ($2.00) per share for the year, up from their prior estimate of ($2.18). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. William Blair also issued estimates for Solid Biosciences’ Q4 2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.74) EPS.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

A number of other brokerages have also recently commented on SLDB. Cantor Fitzgerald set a $16.00 target price on Solid Biosciences and gave the company an “overweight” rating in a report on Monday, July 21st. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Tuesday. Wedbush decreased their target price on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 13th. Barclays set a $9.00 target price on Solid Biosciences and gave the company an “overweight” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Trading Down 10.9%

Shares of SLDB stock opened at $3.93 on Thursday. The company has a market capitalization of $306.03 million, a P/E ratio of -1.58 and a beta of 2.75. The business’s 50 day moving average is $5.62 and its two-hundred day moving average is $5.05. Solid Biosciences has a 12-month low of $2.41 and a 12-month high of $7.37.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SLDB. China Universal Asset Management Co. Ltd. grew its position in Solid Biosciences by 80.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 15,308 shares of the company’s stock worth $57,000 after acquiring an additional 6,836 shares during the period. CWM LLC boosted its position in shares of Solid Biosciences by 15,188.5% during the first quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after buying an additional 7,898 shares during the period. Allianz Asset Management GmbH purchased a new position in shares of Solid Biosciences during the first quarter worth $100,000. XTX Topco Ltd purchased a new position in shares of Solid Biosciences during the first quarter worth $151,000. Finally, Sfmg LLC purchased a new position in Solid Biosciences in the first quarter valued at $93,000. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.